Recipharm and Synthonics Join Forces to Promote Novel Drug Delivery Technology

Recipharm Pharmaceutical Development AB and Synthonics, Inc. have announced the formation of a Joint Promotion Agreement. The contract, the first of its kind to be entered into between the two companies, will provide Recipharm customers full access to Synthonics’ metal coordination chemistry, improving the delivery and performance of their compounds.

Recipharm, a Swedish corporation, provides services that assist pharmaceutical companies throughout Europe, the United States, Japan and further afield with the development and formulation of products. Synthonics, a U.S. corporation, has developed a proprietary metal coordination chemistry that can significantly improve a compound’s delivery and absorption.

Recipharm Pharmaceutical Development’s General Manager, Maria Lundberg, commented: “We are pleased to partner with Synthonics to expand the services and solutions that we can offer our clients. The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products. Furthermore, our ability to offer such services through this novel partnership distinguishes us from other CDMOs.”

Ken Slepicka, CEO of Synthonics, stated that “Synthonics is delighted to partner with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm’s formulation and development teams and believe that our chemistry will fit well in their existing tool kit of solutions. We expect this agreement to help us reach new clients and to expand the use of our chemistry.”